EQS News: Immunic to host R&D day on multiple sclerosis in September and participate in scientific and investor conferences

Immunic is organizing an R&D day on multiple sclerosis in September and is participating in scientific and investor conferences

NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day in September and participate in the following scientific and investor conferences:

• September 10: Immunic’s MS R&D Day. Immunic’s leadership, including Daniel Vitt, Ph.D., Chief Executive Officer; Jason Tardio, MBA, Chief Operating Officer and President; Andreas Muehler, MD, MBA, Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, will be joined by two renowned MS industry experts to discuss the MS landscape, as well as Immunic’s orally available lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), and its potential to become the treatment of choice for both relapsing and progressive MS patients.
  • Date: Tuesday, September 10, 2024
  • Time: 10:30am – 12:30pm ET, followed by a networking lunch
  • Location: One Five One, 151 West 42nd Street, New York, NY 10036
  • Featured Experts:
    • Francesca Montarolo, Ph.D., Neuroscience Institute Cavalieri Ottolenghi (NICO) and University Hospital San Luigi Gonzaga of Orbassano, Turin, Italy
    • Amit Bar-Or, MD, FRCPC, Melissa and Paul Anderson Distinguished Chair, Director, Center for Neuroinflammation and Experimental Therapeutics, Chief of the Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania
  • RegisterYou can register by sending an email to: (email protected).

• September 18-20: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Members of Immunic’s management, medical, clinical and preclinical teams will attend the conference in Copenhagen, Denmark. Data on vidofludimus calcium will be presented in an oral presentation and three ePosters. In addition, the team will be available at booth #60 throughout the event. All poster presentations can be accessed in the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.
• Oral poster presentation:
  • Title: Serum neurofilament changes in progressive MS: investigating the impact of vidofludimus calcium on age and disability in the CALLIPER study interim analysis
  • Presenting author: Robert J. Fox, Staff Neurologist, Mellon Center for Multiple Sclerosis, Vice Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
  • Poster number: P753
  • Session title: Poster session 2
  • Session date: Thursday, September 19, 2024
  • Session time: 16:45 – 18:45 CEST
• ePosters:
  • Title: Investigating the potential of Vidofludimus Calcium to reduce fatigue in multiple sclerosis by preventing reactivation of the Epstein-Barr virus
  • ePoster number: P1119
  • Title: Vidofludimus Calcium activity on NURR1 in preclinical models: a potential neuroprotective role in multiple sclerosis
  • ePoster number: P1410
  • Title: Vidofludimus Calcium Shows T Helper Cell Modulatory Effects in Experimental Murine Autoimmune Encephalomyelitis: One Possible Mode of Action for the Treatment of MS
  • ePoster number: P1390

• September 2-4: DMDG-50^and Public meeting 2024. Juliano R. Fonseca, Ph.D., head of preclinical development at Immunic, will present data from Immunic’s open-label mass balance and pharmacokinetic phase 1 study of vidofludimus calcium in a poster presentation at the meeting in York, United Kingdom.
  • Title: Mass balance and ADME properties of (¹⁴C)-IMU-838 After oral administration to healthy male subjects
  • The presentation and specific poster number and session details can be found in the ‘Events and Presentations’ section of the Immunic website: https://ir.imux.com/events-and-presentations, as soon as they become available.

• September 5-7: 20^and International Celiac Disease Symposium ICDS. Martina Wirth, Senior Manager Translational Pharmacology at Immunic, will present data from Immunic’s Phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a groundbreaking poster presentation at this symposium in Sheffield, United Kingdom.
  • Title: First-in-human trial of IMU-856, an orally available epigenetic modulator of barrier function and regeneration for the treatment of celiac disease
  • The presentation and specific poster number and session details can be found in the ‘Events and Presentations’ section of the Immunic website: https://ir.imux.com/events-and-presentations, as soon as they become available.
• September 17-19: Cantor Fitzgerald Global Healthcare Conference 2024. Dr. Vitt will participate in a fireside chat at the conference in New York on Wednesday, September 18, 2024 at 3:05 p.m. ET. A webcast of the presentation will be available in the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations. An archived replay will be available on the company’s website for a period of 90 days following the conference.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapeutics for chronic inflammatory and autoimmune diseases. The Company’s lead development program, vidofludimus calcium (IMU-838), is currently in Phase 3 and Phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has demonstrated therapeutic activity in Phase 2 clinical trials in patients with relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate to severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and antiviral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the Sirtuin 6 (SIRT6) protein, is intended to restore intestinal barrier function and regenerate intestinal epithelium, which could potentially be applicable to numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparation for a Phase 2 clinical trial. IMU-381, currently in preclinical testing, is a next-generation molecule being developed specifically to address the needs of gastrointestinal diseases. For more information, please visit: www.imux.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve significant risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release regarding strategy, future operations, future financial position, future revenues, expected expenses, adequacy of cash and cash flows, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding management’s and employees’ participation in investor and scientific conferences. Immunic may not actually achieve the plans, realize the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve significant risks and uncertainties. Actual results and performance may differ materially from those projected in the forward-looking statements as a result of many factors, including, but not limited to, the COVID-19 pandemic, increasing inflation, the effects of the Ukraine-Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to predict future cash uses and reserves for contingent liabilities and business activities, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that results from prior preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity afforded by Immunic’s intellectual property, risks related to drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this press release speaks only as of the date of this press release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date on which they are made. Immunic expressly disclaims any liability for any actions taken or not taken based on the contents of this press release.

Contact details

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
(email address)

US IR Contact
Rx Communication Group
Paula Schwartz
+1 917 633 7790
(email address)

Contact person for the American media
KCSA Strategic Communication
Caitlin Kasunich
+1 212 896 1241
(email address)